Pharma Industry News
A collection of Pharma latest news, analysis and best practices from top business influencers and the world's most trustworthy sources.
Bayer to Invest $2.2 Billion in U.S. Pharma Manufacturing Expansion
The German company's pharma business has been looking to expand in the U.S., betting that an enlarged presence in the world's largest drug market can help it revive sales growth after two key products went off patent.
Bayer to Invest $2.2 Billion in U.S. Pharma Manufacturing Expansion
said it plans to spend $2.2 billion to build a new manufacturing site in Ohio for its pharmaceutical business, becoming the latest European drugmaker to invest in the U.S. The German agricultural and pharmaceutical group said Friday that its new…
Big Pharma turns to China for new drugs as patent cliff drives multibillion-dollar deals
Swiss Novartis is entering a licensing agreement with a Chinese biotech worth as much as $7.8 billion. It comes after several pharma peers announced deals with China-based drug developers over the past two weeks. ING estimates that China will…
Why Eric Cantor Going To Head Big Pharma Is Super Swampy
That cynical reaction perfectly summed up the recent news that former House Majority Leader Eric Cantor, R-Va., will become the next head of the Pharmaceutical Research and Manufacturers of America (PhRMA) in November. If not exactly a match made…
Insider Selling: NewAmsterdam Pharma (NASDAQ:NAMS) Insider Sells $1,257,657.38 in Stock
NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS - Get Free Report) insider Johannes Kastelein sold 50,246 shares of the stock in a transaction dated Wednesday, September 30th. The stock was sold at an average price of $25.03, for a total transaction…
The cost of convenience: Why big pharma must choose independence over short-term profits - Ya Libnan
Photo illustration -“Investing in AI, research and pharmaceutical manufacturing today can protect tomorrow's patients from dependence and blackmail.” True innovation is not just about discovering a cure—it is about ensuring you…
Big Pharma's China deals worth billions: Chinese biotech out licensing deals to surpass $250 billion in 2026 - Ya Libnan
Novartis has signed a deal worth up to $7.8 billion, in the latest of a flurry of tie-ups between Big Pharma and Chinese biotechs. The Swiss pharma major is entering a licensing agreement with China-based Abogen Biosciences for its lead asset, an…
NewAmsterdam Pharma (NASDAQ:NAMS) Stock Price Down 5.2% - Time to Sell?
NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS - Get Free Report)'s share price traded down 5.2% during mid-day trading on Friday. The stock traded as low as $22.98 and last traded at $22.9150. 469,005 shares changed hands during trading, a decline…
Cipla faces fresh FDA blow, Pune warehouse drug licences cancelled
The Maharashtra Food and Drug Administration has cancelled the drug sale and distribution licences for Cipla Pharma & Life Sciences Ltd's Pune warehouse, citing significant violations related to misbranding and storage of the Schedule H drug…
FDA cancels drug sale licence of Cipla facility in Pune
The Maharashtra Food and Drug Administration (FDA) on Friday said it has cancelled the drug sale and distribution licences of Cipla Pharma & Life Sciences Ltd's carrying and forwarding (C&F) warehouse at Wadki in Pune following detection of alleged…
Novartis signs $7.8 billion drug deal with Chinese startup
Novartis on Friday signed a drug licensing deal with China's Abogen Biosciences that could be worth up to $7.8 billion. Why it matters: This is the latest example of a Western pharma giant partnering with a Chinese biotech — a trend that…
Pfizer Is Down 34% Over the Last 5 Years. Here's Why Its 6% Dividend Yield Might Finally Be Worth the Risk.
If you've been looking for high-yield stocks, Pfizer (PFE -1.40%) may have crossed your radar screen. As shares of the pharma giant slipped over the past few years, its dividend yield marched higher, and in recent times, settled at 6%. High…
American Healthcare REIT: A Dip Buy Driven By Senior-Care And Outpatient Tailwind (NYSE:AHR)
Albert Anthony is the pen name of a business author on Amazon and his newest book is 'How To Pick Stocks: 8 Steps For Long-Term Investing with Fundamental & Technical Analysis,' now available as a 2026 edition paperback and Kindle ebook in several…
Prediction: Eli Lilly Could Be the Next $2 Trillion Drugmaker
Eli Lilly (NYSE:LLY | LLY Price Prediction) trades at $1,184.92, which gives it a market value of about $1.057 trillion. The 24/7 Wall St. price target for Eli Lilly is $1,401.42 over the next 12 months. That means 18.27% upside and earns a…
Novo Nordisk Strikes Nearly $4 Billion in 2 Deals. Here's What That Means for Investors
Novo Nordisk (NVO -0.21%) is looking to maintain its position in the weight-loss market and one-up its most important competitor, Eli Lilly (LLY -0.61%). To that end, the Denmark-based pharmaceutical giant has developed several promising…
Receive a Daily briefing on Pharma Industry News
Get Started